Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.35 |
| ▸ | ITGAL | P20701 | 3/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 4/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.33 |
| ▸ | ITGAV | P06756 | 3/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21957169 | 1.00 | KDR (0.35) | KDRMETITGB2ICAM1ITGAL | |
| SCHEMBL22017214 | 0.92 | ITGB1 (0.35) | KDRMETITGB2ICAM1ITGAL | |
| SCHEMBL22016649 | 0.91 | ITGB1 (0.38) | ITGB2ICAM1ITGALITGB1ITGA4 | |
| SCHEMBL22016320 | 0.91 | ITGB1 (0.38) | ITGB2ICAM1ITGALITGB1ITGA4 | |
| SCHEMBL21957200 | 0.88 | KDR (0.36) | KDRMETITGB2ICAM1ITGAL | |
| SCHEMBL21957197 | 0.88 | KDR (0.36) | KDRMETITGB2ICAM1ITGAL | |
| SCHEMBL22016395 | 0.88 | ITGB2 (0.35) | ITGB2ICAM1ITGALITGB1ITGA4 | |
| SCHEMBL22017016 | 0.87 | ITGB1 (0.36) | ITGB2ICAM1ITGALITGB1ITGA4 | |
| SCHEMBL22017536 | 0.86 | ITGB1 (0.34) | ITGB2ICAM1ITGALITGB1ITGA4 | |
| SCHEMBL22017003 | 0.86 | ITGB2 (0.38) | ITGB2ICAM1ITGALITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4541422-A2 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | Gilead Sciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3873884-B1 | 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDIN-2,4-DIONE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-12053462-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053462-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | KDR 4582/4885MET 4742/4885ITGB2 2856/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDR 4582/4885MET 4742/4885ITGB2 2856/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDR 4582/4885MET 4742/4885ITGB2 2856/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | KDR 1365/4885MET 4063/4885ITGB2 7/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | KDR 4582/4885MET 4742/4885ITGB2 2856/4885 |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDR 4582/4885MET 4742/4885ITGB2 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.